Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Withdrawn 1Unknown 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 211Thoracic 72Head & Neck 25Other solid neoplasm 13Gynecologic 13Lymphoid 10Breast 8Tumor-Agnostic 7CNS 6Sarcoma 4Genitourinary 4Endocrine 3Other neoplasm 2NET 2Dermatologic 2Myeloid 1

Conditions

Neoplasms 1Melanoma 1Lymphoma, T-Cell, Cutaneous 1

Interventions

pembrolizumab 326Nivolumab 289Ipilimumab 260Cyclophosphamide 193aldesleukin 145Interleukin-2 109fludarabine phosphate 106Temozolomide 83Dacarbazine 81fludarabine 80Radiotherapy 74trametinib 73Vemurafenib 69dabrafenib 66Biopsy 65sargramostim 50Bevacizumab 50Radiosurgery 49Paclitaxel 49Peripheral Blood Stem Cell Transplantation 48Carboplatin 48Magnetic Resonance Spectroscopy 47Imiquimod 47Aminolevulinic Acid 47binimetinib 45Cisplatin 45CTLA-4 Antigen 43cemiplimab 42atezolizumab 41Specimen Handling 40

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Interventional × sintilimab × Dermatologic × Clear all
NCT05572463 2022-11-18

A Platform Study of Novel Immunotherapy Products in Participants With Previously Treated Unresectable or Metastatic Cutaneous Melanoma

Innovent Biologics (Suzhou) Co. Ltd.

Phase 1/2 Withdrawn
Dermatologic

Melanoma, Neoplasms

NCT04296786 2020-03-05

Sintilimab Plus Chidamide in the Treatment of Relapsed and Refractory Cutaneous T-cell Lymphoma: a Multicenter Phase II Study

Peking Union Medical College Hospital

Phase 2 Unknown
52 enrolled
DermatologicLymphoid

Lymphoma, T-Cell, Cutaneous

Data powered by HemOnc (CC BY 4.0) Colophon âš¡